Impact of the life sciences on organisation and management of R&D in large pharmaceutical firms Online publication date: Tue, 18-Nov-2008
by James Mittra
International Journal of Biotechnology (IJBT), Vol. 10, No. 5, 2008
Abstract: The life sciences are having a significant impact on the organisation and management of R&D in large pharmaceutical firms, as well as restructuring the markets for new therapeutic products. However, there is continuing scepticism about large firms' ability or inclination to build in-house capacity for biologics and extract value from the life sciences. This paper explores the effect of life science innovation on early and late-stage R&D, and considers the implications for strategic management and the transition of compounds through the middle stages of the R&D pathway. The analysis, which includes two company case studies, reveals that new life science technologies have had a marginal impact on late-stage R&D, but companies are exploring new organisational or translational models to better exploit the science and reduce the phase 2 attrition rates. Findings suggest that firms have the capability to adapt to a new innovation trajectory, but external pressures on strategic and organisational management will continue to determine the level and rate of success.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Biotechnology (IJBT):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook